Assesment of cardiac effects of ado-trastuzumab emtansine through strain rate imaging in metastatic breast cancer.

e13007Background: Human epidermal growth factor receptor- (HER2-) targeted therapy with the he antibody-drug conjugate Ado-trastuzumab emtansine (T-DM1) has revolutionized the management of HER2-positive metastatic breast cancer (MBC). Although well-tolerated , cardiotoxicity has been documented. Sequential left ventricular (LV) ejection fraction (EF) assessment has been mandated to detect myocardial dysfunction. Changes in cardiac function induced by this therapy, however, are difficult to quantitate by conventional echocacardiography. Tissue Doppler myocardial imaging (TDI) derived wall motion velocity, and strain rate (SR) have been shown to sensitively quantify abnormalities in cardiac function. The aim of this study was to determine if sensitive indices of LV dysfunction, would be useful for addressing the early detection of cardiotoxic side effects of TDM1. Methods: Patients (N = 36 median age 56.8 years) with HER2-positive MBC who had received prior therapy with a taxane plus trastuzumab, received ...